UY26482A1 - Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales - Google Patents
Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina dualesInfo
- Publication number
- UY26482A1 UY26482A1 UY26482A UY26482A UY26482A1 UY 26482 A1 UY26482 A1 UY 26482A1 UY 26482 A UY26482 A UY 26482A UY 26482 A UY26482 A UY 26482A UY 26482 A1 UY26482 A1 UY 26482A1
- Authority
- UY
- Uruguay
- Prior art keywords
- receptor antagonists
- sulphonamides
- biphenyl
- angiotensin receptor
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los nuevos compuestos de bifenil sulfonamida los cuales son antagonistas del receptor de angiotensina y endotelina combinadas, se reivindican junto con los métodos de uso de tales compuestos en el tratamiento de las condiciones tales como hipertensión y otras enfermedades, así como también las composiciones farmacéuticas que contienen tales compuestos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46403799A | 1999-12-15 | 1999-12-15 | |
US48119700A | 2000-01-11 | 2000-01-11 | |
US51377900A | 2000-02-25 | 2000-02-25 | |
US60432200A | 2000-06-26 | 2000-06-26 | |
US64364000A | 2000-08-22 | 2000-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26482A1 true UY26482A1 (es) | 2001-07-31 |
Family
ID=27541688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26482A UY26482A1 (es) | 1999-12-15 | 2000-12-14 | Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1237888B1 (es) |
JP (1) | JP2003520785A (es) |
AR (1) | AR029417A1 (es) |
AT (1) | ATE339417T1 (es) |
AU (1) | AU2092601A (es) |
CA (1) | CA2395088A1 (es) |
CO (1) | CO5450242A1 (es) |
DE (1) | DE60030764T2 (es) |
ES (1) | ES2273739T3 (es) |
PE (1) | PE20010930A1 (es) |
UY (1) | UY26482A1 (es) |
WO (1) | WO2001044239A2 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
AU2002257970B2 (en) | 2001-05-31 | 2007-08-02 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin II agonists |
MXPA04004674A (es) | 2001-11-14 | 2004-08-12 | Schering Corp | Ligados de los receptors de los canabinodies. |
TWI328007B (en) | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
EP1539693B9 (en) | 2002-06-19 | 2008-10-08 | Schering Corporation | Cannabinoid receptor agonists |
GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
WO2004085420A1 (en) * | 2003-03-24 | 2004-10-07 | Vicore Pharma Ab | Bicyclic compounds useful as angiotensin ii agonists |
EP1660183A2 (en) * | 2003-05-05 | 2006-05-31 | Eli Lilly and Company | Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4) |
DE10336497B4 (de) * | 2003-08-08 | 2007-04-05 | Freie Universität Berlin | Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
DK1830869T3 (da) | 2004-12-24 | 2013-08-26 | Spinifex Pharm Pty Ltd | Fremgangsmåde til behandling eller profylakse |
AU2007221495B2 (en) * | 2006-03-03 | 2011-09-15 | Torrent Pharmaceuticals Ltd. | Novel dual action receptors antagonists (DARA) at the AT1 and ETA receptors |
WO2007109456A2 (en) * | 2006-03-16 | 2007-09-27 | Pharmacopeia, Inc. | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists |
AU2012203919B2 (en) * | 2006-03-20 | 2014-10-23 | Novartis Ag | Method of treatment or prophylaxis of inflammatory pain |
JP5230595B2 (ja) | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 炎症性疼痛の治療または予防の方法 |
WO2008073365A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors |
TW200838501A (en) * | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
WO2009155448A1 (en) * | 2008-06-20 | 2009-12-23 | Ligand Pharmaceuticals Inc. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
WO2009158309A2 (en) * | 2008-06-25 | 2009-12-30 | Ligand Pharmaceuticals Inc. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
HUE049450T2 (hu) * | 2009-03-31 | 2020-09-28 | Ligand Pharm Inc | Endotelin és angiotenzin II receptor antagonista bifenilszulfonamid glomeruloszklerózis és IgA által kiváltott nefropátia kezelésére |
ES2611107T3 (es) * | 2009-07-07 | 2017-05-04 | Theravance Biopharma R&D Ip, Llc | Agentes antihipertensivos de pirazol, de doble acción |
CN104761548B (zh) * | 2015-04-27 | 2017-09-12 | 梯尔希(南京)药物研发有限公司 | 一种稳定同位素标记的二苯基磺酰胺类药物的制备方法 |
WO2018071784A1 (en) | 2016-10-13 | 2018-04-19 | Retrophin, Inc. | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders |
US10703723B2 (en) | 2017-03-09 | 2020-07-07 | Truly Translational Sweden Ab | Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease |
WO2018220101A1 (en) | 2017-05-31 | 2018-12-06 | Truly Translational Sweden Ab | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy |
US11365194B2 (en) * | 2017-09-27 | 2022-06-21 | Kagoshima University | Analgesic drug using PAC1 receptor antagonistic drug |
EP3489222A1 (en) | 2017-11-23 | 2019-05-29 | medac Gesellschaft für klinische Spezialpräparate mbH | Sulfasalazine salts, production processes and uses |
EP3488868B1 (en) | 2017-11-23 | 2023-09-13 | medac Gesellschaft für klinische Spezialpräparate mbH | Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use |
MX2021003606A (es) | 2018-10-04 | 2021-08-16 | Travere Therapeutics Inc | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. |
CA3124127A1 (en) * | 2018-12-21 | 2020-06-25 | Travere Therapeutics, Inc. | Amorphous sparsentan compositions |
CN109928897B (zh) * | 2019-04-01 | 2021-09-14 | 四川大学华西医院 | 防治梗死性疾病的双胍衍生物及其应用 |
WO2022266370A1 (en) | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
EP4393920A1 (en) * | 2021-08-26 | 2024-07-03 | Shanghai Hansoh Biomedical Co., Ltd. | Aromatic ring-containing biological antagonist, and preparation method therefor and use thereof |
WO2023066348A1 (zh) * | 2021-10-21 | 2023-04-27 | 年衍药业(上海)有限公司 | 一种双重拮抗剂及其用途 |
JPWO2023127853A1 (es) * | 2021-12-28 | 2023-07-06 | ||
CN115636799A (zh) * | 2022-11-04 | 2023-01-24 | 苏州莱安医药化学技术有限公司 | 一种双效内皮素-血管紧张素受体拮抗剂的制备方法 |
WO2024175082A1 (zh) * | 2023-02-24 | 2024-08-29 | 江苏豪森药业集团有限公司 | 含芳环类衍生物拮抗剂的盐、其制备方法和应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260328A (en) * | 1989-04-06 | 1993-11-09 | Farmitalia Carlo Erba Srl | Phenyl-indenopurazol 3-oxo-propanamide derivatives useful in the treatment of rheumatoid arthritis |
DE122010000024I1 (de) * | 1990-02-19 | 2010-07-08 | Novartis Ag | Acylverbindungen |
US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
GB2264710A (en) * | 1992-03-04 | 1993-09-08 | Merck & Co Inc | Quinoline and azaquinoline angiotensin ii antagonists incorporating a substituted biphenyl element |
NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
AU675660B2 (en) * | 1992-07-17 | 1997-02-13 | Merck & Co., Inc. | Substituted biphenylmethylimidazopyridines |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
WO1997000256A1 (en) * | 1995-06-15 | 1997-01-03 | Merck & Co., Inc. | Polymorphic forms of an angiotensin ii antagonist |
GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
CA2336714A1 (en) * | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
-
2000
- 2000-12-13 EP EP00984282A patent/EP1237888B1/en not_active Expired - Lifetime
- 2000-12-13 AT AT00984282T patent/ATE339417T1/de not_active IP Right Cessation
- 2000-12-13 WO PCT/US2000/033730 patent/WO2001044239A2/en active IP Right Grant
- 2000-12-13 EP EP06016968A patent/EP1741713A3/en not_active Withdrawn
- 2000-12-13 JP JP2001544729A patent/JP2003520785A/ja not_active Withdrawn
- 2000-12-13 CA CA002395088A patent/CA2395088A1/en not_active Abandoned
- 2000-12-13 ES ES00984282T patent/ES2273739T3/es not_active Expired - Lifetime
- 2000-12-13 DE DE60030764T patent/DE60030764T2/de not_active Expired - Fee Related
- 2000-12-13 AU AU20926/01A patent/AU2092601A/en not_active Abandoned
- 2000-12-14 CO CO00095238A patent/CO5450242A1/es not_active Application Discontinuation
- 2000-12-14 UY UY26482A patent/UY26482A1/es not_active Application Discontinuation
- 2000-12-15 PE PE2000001349A patent/PE20010930A1/es not_active Application Discontinuation
- 2000-12-15 AR ARP000106686A patent/AR029417A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR029417A1 (es) | 2003-06-25 |
ES2273739T3 (es) | 2007-05-16 |
DE60030764T2 (de) | 2007-09-13 |
EP1741713A2 (en) | 2007-01-10 |
EP1237888A2 (en) | 2002-09-11 |
ATE339417T1 (de) | 2006-10-15 |
PE20010930A1 (es) | 2001-11-18 |
WO2001044239A2 (en) | 2001-06-21 |
EP1237888B1 (en) | 2006-09-13 |
WO2001044239A3 (en) | 2001-11-01 |
JP2003520785A (ja) | 2003-07-08 |
CO5450242A1 (es) | 2004-10-29 |
EP1741713A3 (en) | 2009-09-09 |
CA2395088A1 (en) | 2001-06-21 |
DE60030764D1 (de) | 2006-10-26 |
AU2092601A (en) | 2001-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26482A1 (es) | Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales | |
DK1094816T3 (da) | Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister | |
UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
CR8847A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y usos de los mismos | |
CR9591A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
ECSP088324A (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas | |
UY27760A1 (es) | Nuevos derivados de pirrolidinio. | |
PA8496301A1 (es) | Inhibidores de metaloproteasas. | |
UY27729A1 (es) | Inhibidores de quinasas. | |
PA8643201A1 (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa | |
ECSP034428A (es) | Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso | |
DE602004012083D1 (de) | Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren | |
UY28760A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
NO20063393L (no) | Farmasoytiske preparater | |
UY28646A1 (es) | Nuevos antagonistas del receptor muscarinico m3 de acetilcolina | |
UY28645A1 (es) | Nuevos antagonistas del receptor muscarinico m3 de acetilcolina | |
BR9909486A (pt) | Compostos calcilìticos | |
SV2002000005A (es) | Heterociclos 2-arilimino substituidos y composiciones que los contienen para usar como agentes que ligan el receptor de la progesterona ref. 5048p1-sv | |
ECSP034532A (es) | Derivados del 1-aminobutan-3-ol sustituido | |
AR026209A1 (es) | Compuestos monociclicos basicos con accion nk-2 antagonista, procesos de fabricacion y formulas que los contienen | |
ECSP003823A (es) | Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelia duales | |
BRPI0510407A (pt) | derivados de 3-amino-2-fenilpirrolidina | |
UY26809A1 (es) | Moduladores cíclicos fusionados de función de receptor hormonal nuclear | |
MXPA05012279A (es) | Derivados de bencil sulfonamida. | |
CR7442A (es) | Derivados de benzimidazol 1-fenil-2- heteroaril- sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunologicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20120525 |